XDNA

Kelly CRISPR & Gene Editing Tech ETF

Strategic CRISPR & Gene Edit Tech TR USD

NAV as of 28-Sep-2023

7.2631

4 Week: 7.39 - 8.37

52 Week: 7.39 - 12.37

Latest Closing Price

7.42

Premium / Discount

1.72

Expense Ratio

0.78%

Investment Objective

The investment seeks to track the total return performance of the Strategic CRISPR & Gene Editing Technology Index. The adviser employs a “passive management” investment approach designed to track the total return performance of the index. The index is a rules-based index that consists of the stocks or corresponding depositary receipts of companies engaged in the creation, development, production, operation, provision, distribution, ownership, servicing, licensing, leasing or franchising of at least one of the DNA Modification Technology Business. The fund invests at least 80% of its net assets in DNA Modification Technology Companies. It is non-diversified.

Main Fund Characteristics

Fund Manager:
Strategic
Asset Under Management:
2,178,969
Launch Date:
11/01/2022
Asset Class:
Equity
Replication Method:
Physical-Full
Number of Holdings:
25
Trading Currency:
USD
Style:
Small Blend
Region/Sector/Strategy:
N.A / Healthcare / N.A
Exchange:
NASDAQ

Performance

Period Performance Returns(%) Volatility(%) Risk Adjusted Performance
YTD-25.351.98-12.78
1 Day0.140.000.00
1 Week-1.201.66-0.72
1 Month-11.985.13-2.33
3 Months-15.3912.15-1.27
6 Months-16.3520.17-0.81
1 Year-36.1234.13-1.06
2 Years0.000.000.00
3 Years0.000.000.00
5 Years0.000.000.00
10 Years0.000.000.00

Price History

-

Annual Performance Return

2013201420152016201720182019202020212022
Price (%) 0.00000.00000.00000.00000.00000.00000.00000.00000.00000.0000
Nav (%) 0.00000.00000.00000.00000.00000.00000.00000.00000.00000.0000
Rank 0.00000.00000.00000.00000.00000.00000.00000.00000.00000.0000

Dividend Frequency

Lastest Dividend

Ex Date Payment Date Dividend Payout per unit
25/06/202329/06/20230.0800
28/12/202204/01/20230.0433
21/12/202226/12/20220.0093

Portfolio Data

Total Number of Holdings: 25

Number of Bond Holdings: 0

Number of Equity Holdings: 23

Total Market Value: 2,178,969

Portfolio Composition

Top 10 Holdings

% Portfolio Weight Shares Owned Shares Changed Market Value
1Beam Therapeutics Inc11.627910,5480253,363

Country Exposure

Regional Exposure

America

Greater Europe

Greater Asia

Market Classification

Market Capitalization

Size% of portfolio
Giant11.44
Large15.14
Medium15.65
Small9.52
Micro48.01

Equity Style Box Breakdown

000Large
000Mid
000Small
ValueBlendGrowth

Value Measures

Price/Prospective Earnings*

17.3367

Price/Book*

2.1786

Price/Sales*

2.2702

Price/Cash Flow*

14.4345

Dividend Yield*

0.6152

Growth Measures

Long-Term Earnings

5.8097

Historical Earnings

16.2686

Sales Growth

-6.3064

Cash-Flow Growth

-5.2452

Book-Value Growth

-8.3822

*Forward-looking based on historical data.

Equity Sector

Number of Bond Holdings

0

Bond Statitics

DetailValue
Average Effective Duration0
Average Effective Maturity (Years)*0
Average Credit Quality0
Average Weighted Coupon*0
Average Weighted Price*0

Bond Style Box Breakdown

000HighQuality
000Med
000Low
LtdModExt
Interest-Rate Sensitivity

Credit Quality

Type% Bonds
N.A

Bond Sector

Type
% Bonds

Bond Maturity

% Bonds
N.A

Data Source: Morningstar

© 2019 Morningstar. All Rights Reserved. The information, data, analyses and opinions (“Information”) contained herein:

(1) include the proprietary information of Morningstar and Morningstar’s third party licensors;
(2) may not be copied or redistributed except as specifically authorised;
(3) do not constitute investment advice;
(4) are provided solely for informational purposes;
(5) are not warranted to be complete, accurate or timely; and
(6) may be drawn from fund data published on various dates.

Morningstar and Phillip Securities Pte Ltd are not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

For the most up-to-date fund’s data and information, a copy of the fund factsheet, information or prospectus may be obtained from the respective ETF issuer.

Contact us to Open an Account

Need Assistance? Share your Details and we’ll get back to you